BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ziftomenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ziftomenib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06001788-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06001788)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Safety a
 nd Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refra
 ctory Acute Myeloid Leukemia\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06001788
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07411586-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20270114
DTEND;VALUE=DATE:20270115
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT07411586)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Phase 1/
 1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute
  Myeloid Leukemia\nEstimated primary completion: 14 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07411586
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623616-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT07623616)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Phase 
 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM
 1-Mutated Acute Myeloid Leukemia\nEstimated primary completion: March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07623616
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440135-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06440135)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Ziftomen
 ib Maintenance Post Allo-HCT\nEstimated primary completion: 1 April 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06440135
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355335-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT07355335)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Ziftomen
 ib + Mezigdomide in Adolesc. and Adults w/ R/R AML\nEstimated primary comp
 letion: 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ziftomenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07355335
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930352-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ziftomenib: Phase 2 readout est. (NCT06930352)
DESCRIPTION:Ziftomenib\, phase 2\, Acute Myeloid Leukemia.\nStudy: Ziftomen
 ib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acu
 te Myeloid Leukemia Not Eligible for Standard Therapy\nEstimated primary c
 ompletion: 31 January 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ziftomenib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06930352
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769490-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06769490)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Dose Esc
 alation and Expansion of Ziftomenib in Combination With Quizartinib in Acu
 te Myeloid Leukemia\nEstimated primary completion: 15 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06769490
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04067336-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT04067336)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: First 
 in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leuke
 mia\nEstimated primary completion: 16 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT04067336
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05848687-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ziftomenib: Phase 1/2 readout est. (NCT05848687)
DESCRIPTION:Ziftomenib\, phase 1/2\, Acute Lymphoblastic Leukemia.\nStudy: 
 TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT05848687
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448013-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06448013)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Phase 
 I Study Investigating the Combination of the Menin Inhibitor Ziftomenib Wi
 th Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leuk
 emia\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06448013
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06397027-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06397027)
DESCRIPTION:Ziftomenib\, phase 1.\nStudy: A Phase I Study Investigating the
  Combination of the Ziftomenib\, Venetoclax and Azacitidine in Pediatric R
 elapsed and Refractory Acute Leukemias\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ziftome
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06397027
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07929740-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT07929740)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: Bioavail
 ability and Bioequivalence Study of Ziftomenib in Participants With Relaps
 ed/Refractory AML or MDS\nEstimated primary completion: 28 February 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07929740
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655246-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06655246)
DESCRIPTION:Ziftomenib\, phase 1.\nStudy: A Study of Ziftomenib in Combinat
 ion With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumor
 s (GIST)\nEstimated primary completion: June 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06655246
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05735184-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT05735184)
DESCRIPTION:Ziftomenib\, phase 1\, Acute Myeloid Leukemia.\nStudy: A Study 
 to Investigate the Safety and Tolerability of Ziftomenib in Combination Wi
 th Venetoclax/Azacitidine\, Venetoclax\, 7+3\, or 7+3+Quizartinib in Patie
 nts With AML\nEstimated primary completion: April 2030. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ziftomenib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05735184
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007312-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Ziftomenib: Phase 3 readout est. (NCT07007312)
DESCRIPTION:Ziftomenib\, phase 3\, Acute Myeloid Leukemia.\nStudy: Studies 
 to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With U
 ntreated NPM1-m or KMT2A-r AML\nEstimated primary completion: November 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ziftomenib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007312
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06376162-2835@assetmemo.bio
DTSTAMP:20261121T004444Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Ziftomenib: Phase 1 readout est. (NCT06376162)
DESCRIPTION:Ziftomenib\, phase 1.\nStudy: Ziftomenib in Combination With Ch
 emotherapy for Children With Relapsed/Refractory Acute Leukemia\nEstimated
  primary completion: March 2033. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ziftomenib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06376162
URL:https://assetmemo.bio/drug/ziftomenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
